Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Kiromic BioPharma Inc is a biotechnology business based in the US. Kiromic BioPharma shares (KRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Kiromic BioPharma employs 19 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Experienced Investors
| Latest market close | $2.15 |
|---|---|
| 52-week range | $1.81 - $12.11 |
| 50-day moving average | $3.06 |
| 200-day moving average | $5.63 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.24 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.15 from 2021-10-18
| 1 week (2021-10-12) | 6.44% |
|---|---|
| 1 month (2021-09-17) | -37.86% |
| 3 months (2021-07-19) | -26.37% |
| 6 months (2021-04-19) | -75.57% |
| 1 year (2020-10-19) | -80.96% |
|---|---|
| 2 years (2019-10-15) | N/A |
| 3 years (2018-10-15) | N/A |
| 5 years (2016-10-15) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -180.54% |
| Return on equity TTM | -425.08% |
| Profit margin | 0% |
| Book value | $0.66 |
| Market capitalisation | $30.4 million |
TTM: trailing 12 months
There are currently 38,678 Kiromic BioPharma shares held short by investors – that's known as Kiromic BioPharma's "short interest". This figure is 6.8% down from 41,499 last month.
There are a few different ways that this level of interest in shorting Kiromic BioPharma shares can be evaluated.
Kiromic BioPharma's "short interest ratio" (SIR) is the quantity of Kiromic BioPharma shares currently shorted divided by the average quantity of Kiromic BioPharma shares traded daily (recently around 214877.77777778). Kiromic BioPharma's SIR currently stands at 0.18. In other words for every 100,000 Kiromic BioPharma shares traded daily on the market, roughly 180 shares are currently held short.
To gain some more context, you can compare Kiromic BioPharma's short interest ratio against those of similar companies.
However Kiromic BioPharma's short interest can also be evaluated against the total number of Kiromic BioPharma shares, or, against the total number of tradable Kiromic BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kiromic BioPharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Kiromic BioPharma shares in existence, roughly 0 shares are currently held short) or 0.0039% of the tradable shares (for every 100,000 tradable Kiromic BioPharma shares, roughly 4 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kiromic BioPharma.
Find out more about how you can short Kiromic BioPharma stock.
We're not expecting Kiromic BioPharma to pay a dividend over the next 12 months.
You may also wish to consider:
Kiromic BioPharma, Inc. , a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc. ; and Longwood University, as well as research and development collaboration agreements with Molipharma, S. R. L.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
